[News] A Personalized Cancer Vaccine Clears Its Biggest Test Yet
A vaccine built from each patient's own tumour cut the risk of melanoma returning or death by 42% on top of the standard immunotherapy in a blinded trial of 1,137 people, the first individualized neoantigen therapy to win a Phase 3 test, though survival data are immature, no price has been disclosed and the first dose takes about two months to reach the patient.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.